Amicus TherapeuticsFOLD
About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Employees: 499
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $1.56M
47% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 79
2.5% more ownership
Funds ownership: 100.72% [Q1] → 103.22% (+2.5%) [Q2]
6% less funds holding
Funds holding: 281 [Q1] → 263 (-18) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
27% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 48
28% less capital invested
Capital invested by funds: $2.53B [Q1] → $1.82B (-$704M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Jeffrey Hung | 1,344%upside $108 | Overweight Upgraded | 17 Jul 2025 |
Financial journalist opinion
Based on 12 articles about FOLD published over the past 30 days
